Literature DB >> 19350001

The curious case of clioquinol.

Lauren Cahoon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19350001     DOI： 10.1038/nm0409-356

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  9 in total

1.  Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

Authors:  R A Cherny; C S Atwood; M E Xilinas; D N Gray; W D Jones; C A McLean; K J Barnham; I Volitakis; F W Fraser; Y Kim; X Huang; L E Goldstein; R D Moir; J T Lim; K Beyreuther; H Zheng; R E Tanzi; C L Masters; A I Bush
Journal:  Neuron       Date:  2001-06       Impact factor: 17.173

2.  Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

Authors:  Lars Lannfelt; Kaj Blennow; Henrik Zetterberg; Stellan Batsman; David Ames; John Harrison; Colin L Masters; Steve Targum; Ashley I Bush; Ross Murdoch; Janet Wilson; Craig W Ritchie
Journal:  Lancet Neurol       Date:  2008-07-30       Impact factor: 44.182

3.  Epidemiological approach to SMON (subacute myelo-optico-neuropathy).

Authors:  I Shigematsu; H Yanagawa; S Yamamoto; K Nakae
Journal:  Jpn J Med Sci Biol       Date:  1975

4.  Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.

Authors:  Deepinder Kaur; Ferda Yantiri; Subramanian Rajagopalan; Jyothi Kumar; Jun Qin Mo; Rapee Boonplueang; Veena Viswanath; Russell Jacobs; Lichuan Yang; M Flint Beal; Dino DiMonte; Irene Volitaskis; Lisa Ellerby; Robert A Cherny; Ashley I Bush; Julie K Andersen
Journal:  Neuron       Date:  2003-03-27       Impact factor: 17.173

5.  Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.

Authors:  Trent Nguyen; Aaron Hamby; Stephen M Massa
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-08       Impact factor: 11.205

6.  Relation between subacute myelo-optic neuropathy (S.M.O.N.) and clioquinol: nationwide survey.

Authors:  K Nakae; S Yamamoto; I Shigematsu; R Kono
Journal:  Lancet       Date:  1973-01-27       Impact factor: 79.321

7.  Anticancer activity of the antibiotic clioquinol.

Authors:  Wei-Qun Ding; Bolin Liu; Joshua L Vaught; Hanako Yamauchi; Stuart E Lind
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

8.  The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1.

Authors:  Ying Wang; Robyn Branicky; Zaruhi Stepanyan; Melissa Carroll; Marie-Pierre Guimond; Abdelmadjid Hihi; Steve Hayes; Kevin McBride; Siegfried Hekimi
Journal:  J Biol Chem       Date:  2008-10-15       Impact factor: 5.157

9.  Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

Authors:  Craig W Ritchie; Ashley I Bush; Andrew Mackinnon; Steve Macfarlane; Maree Mastwyk; Lachlan MacGregor; Lyn Kiers; Robert Cherny; Qiao-Xin Li; Amanda Tammer; Darryl Carrington; Christine Mavros; Irene Volitakis; Michel Xilinas; David Ames; Stephen Davis; Konrad Beyreuther; Rudolph E Tanzi; Colin L Masters
Journal:  Arch Neurol       Date:  2003-12
  9 in total
  19 in total

Review 1.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

2.  Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1-42) oligomer assembly.

Authors:  Harry LeVine; Qunxing Ding; John A Walker; Randal S Voss; Corinne E Augelli-Szafran
Journal:  Neurosci Lett       Date:  2009-08-05       Impact factor: 3.046

3.  Small molecule modulators of copper-induced Abeta aggregation.

Authors:  Sarmad S Hindo; Allana M Mancino; Joseph J Braymer; Yihong Liu; Subramanian Vivekanandan; Ayyalusamy Ramamoorthy; Mi Hee Lim
Journal:  J Am Chem Soc       Date:  2009-11-25       Impact factor: 15.419

Review 4.  Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Tamar Amit
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

5.  Chlamydophila pneumoniae Infection and Its Role in Neurological Disorders.

Authors:  Carlo Contini; Silva Seraceni; Rosario Cultrera; Massimiliano Castellazzi; Enrico Granieri; Enrico Fainardi
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-02-21

Review 6.  Clioquinol: To harm or heal.

Authors:  Dominique R Perez; Larry A Sklar; Alexandre Chigaev
Journal:  Pharmacol Ther       Date:  2019-03-18       Impact factor: 12.310

7.  Combination treatment with fasudil and clioquinol produces synergistic anti-tumor effects in U87 glioblastoma cells by activating apoptosis and autophagy.

Authors:  Mingliang He; Ming Luo; Qingyu Liu; Jingkao Chen; Kaishu Li; Meiguang Zheng; Yinlun Weng; Leping Ouyang; Anmin Liu
Journal:  J Neurooncol       Date:  2016-01-02       Impact factor: 4.130

8.  Bifunctional compounds for controlling metal-mediated aggregation of the aβ42 peptide.

Authors:  Anuj K Sharma; Stephanie T Pavlova; Jaekwang Kim; Darren Finkelstein; Nicholas J Hawco; Nigam P Rath; Jungsu Kim; Liviu M Mirica
Journal:  J Am Chem Soc       Date:  2012-04-06       Impact factor: 15.419

Review 9.  Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.

Authors:  Garth J S Cooper
Journal:  Drugs       Date:  2011-07-09       Impact factor: 9.546

10.  Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline).

Authors:  Hongchao Jiang; Jori E Taggart; Xiaoxi Zhang; Doris M Benbrook; Stuart E Lind; Wei-Qun Ding
Journal:  Cancer Lett       Date:  2011-07-06       Impact factor: 8.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.